Translate page


Collage COLT module 2         Prof. Melo             Prof. Hughes     A/Prof. Branford


Session 1: Front line Therapy of CML-CP

  • Addressing key biological questions in CML 
    (Prof. Junia Melo)
  • Risk profiles, molecular targets, pharmacokinetics 
    (Prof. Timothy Hughes)
  • The importance of deep molecular response in CML patients 
    (A/Prof. Susan Branford) 


Junia Melo COLT 2014


Addressing the Key Biological Questions in CML

Prof. Junia Melo - University of Adelaide

  • Pitfalls of tyrosine kinase inhibitor therapy
  • The role of B-lymphoid kinase (Blk) in CML development
  • Regulation of Blk and the role of Pax5 and cyclin-dependent kinase inhibitor p27
  • Critical molecular pathways in LSCs
  • Other key biological questions


NEW PHOTO Hughes T 02-mod2


Risk Profiles, Molecular Targets and Pharmacokinetics
Prof. Timothy Hughes - SA Pathology, University of Adelaide

  • Ways to optimize CML Therapy:
    • Towards an accurate risk profile
    • Early molecular response
    • Kinase inibition/pharmacokinetics
  • Study results from the ENESTxtnd sub-study of Australian patients
    and the OPTIM Dasatinib trial

Susan Branford COLT 2014




The Importance of Deep Molecular Response for Patients with CML
A/Prof. Susan Branford - Centre for Cancer & Biology, Universities of Adelaide and South Australia

  • Importance of deep molecular reponse in CML
  • Time duration to achieve deep molecular response
  • Factors associated with deep molecuar response
  • Discontinuation trial criteria
  • Patient cases and clinical studies with patients on imatinib based therapy